In contrast to serum IGF-1, IGF-1R activity, especially cytoplasmic and nuclear IGF-1R expression, has been proven to promote radiotherapy resistance and enhance the risk of biological cancer recurrence [41]. This evidence concerns the gene IGF1 and cancer.